SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-011792
Filing Date
2024-08-12
Accepted
2024-08-12 06:50:43
Documents
15
Period of Report
2024-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20240812x8k.htm   iXBRL 8-K 35788
2 EX-99.1 ymab-20240812xex99d1.htm EX-99.1 258933
3 GRAPHIC ymab-20240812xex99d1001.jpg GRAPHIC 5043
  Complete submission text file 0001558370-24-011792.txt   440978

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20240812.xsd EX-101.SCH 3401
5 EX-101.LAB ymab-20240812_lab.xml EX-101.LAB 15928
6 EX-101.PRE ymab-20240812_pre.xml EX-101.PRE 10320
17 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240812x8k_htm.xml XML 4845
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 241194685
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)